Cardiovascular morbidity · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion showed no clear difference in cardiovascular morbidity compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion probably leads to higher all adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Cardiovascular morbidity · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Change in body weight as compared to placebo [kg] from baseline to end of study · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Orlistat probably leads to higher serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
It is very uncertain whether orlistat changes all adverse events compared with placebo (very low certainty).
1 finding from 1 review
Change in body weight as compared to placebo [kg] from baseline to end of study · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Total mortality · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Cardiovascular morbidity · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Total mortality · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Cardiovascular morbidity Combined endpoint: necessity of reinstating antihypertensive therapy and severe cardiovascular complications · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in weight (kg) · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Intervention not reported
Overall mortality · alcohol consumers with high blood pressure
The intervention showed no clear difference in overall mortality (low certainty).
1 finding from 1 review
Intervention not reported
Cardiovascular events · alcohol consumers with high blood pressure
It is very uncertain whether the intervention changes cardiovascular events (very low certainty).
1 finding from 1 review
Intervention not reported
Decrease in alcohol intake (g) · alcohol consumers with high blood pressure
1 finding from 1 review
Intervention not reported
Proportion of subjects with SBP < 140 mmHg and DBP < 90 mmHg · alcohol consumers with high blood pressure
It is very uncertain whether the intervention changes proportion of subjects with SBP < 140 mmHg and DBP < 90 mmHg (very low certainty).
1 finding from 1 review
Secondary outcome: all adverse events · People who may be at risk for primary hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical attachment level (CAL) · Adults (any age/sex) with chronic periodontitis (>=5 teeth remaining; PPD >4 mm), with or without hypertension
Periodontal treatment (subgingival SRP with or without other… led to lower clinical attachment level (CAL) compared with no treatment (no periodontal treatment); GRADE not reported.
1 finding from 1 review